WO2008038119A2 - Composition contenant un complexe de coenzyme q10 et de cyclodextrines et son utilisation pour le traitement de pathologies du système nerveux central - Google Patents
Composition contenant un complexe de coenzyme q10 et de cyclodextrines et son utilisation pour le traitement de pathologies du système nerveux central Download PDFInfo
- Publication number
- WO2008038119A2 WO2008038119A2 PCT/IB2007/002820 IB2007002820W WO2008038119A2 WO 2008038119 A2 WO2008038119 A2 WO 2008038119A2 IB 2007002820 W IB2007002820 W IB 2007002820W WO 2008038119 A2 WO2008038119 A2 WO 2008038119A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- treatment
- production
- cyclodextrin
- drug
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 title claims abstract description 19
- 150000001746 carotenes Chemical class 0.000 title claims abstract description 18
- 235000005473 carotenes Nutrition 0.000 title claims abstract description 18
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 8
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title description 5
- 230000001575 pathological effect Effects 0.000 title description 5
- 239000005515 coenzyme Substances 0.000 claims abstract description 40
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- 239000001116 FEMA 4028 Substances 0.000 claims description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 12
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 12
- 229960004853 betadex Drugs 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 7
- 235000013734 beta-carotene Nutrition 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 7
- 229960002747 betacarotene Drugs 0.000 claims description 7
- 230000036542 oxidative stress Effects 0.000 claims description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims description 4
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 claims description 4
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 208000007530 Essential hypertension Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 208000007466 Male Infertility Diseases 0.000 claims description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 2
- 235000003903 alpha-carotene Nutrition 0.000 claims description 2
- 239000011795 alpha-carotene Substances 0.000 claims description 2
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 2
- 206010003883 azoospermia Diseases 0.000 claims description 2
- 125000001409 beta-carotene group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 208000011851 neurological alteration Diseases 0.000 claims description 2
- 208000008634 oligospermia Diseases 0.000 claims description 2
- 230000036616 oligospermia Effects 0.000 claims description 2
- 231100000528 oligospermia Toxicity 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- 230000004382 visual function Effects 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 abstract description 15
- 229940097362 cyclodextrins Drugs 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001782 photodegradation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 238000001033 granulometry Methods 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- -1 superoxide anions Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 210000001587 telencephalon Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/15—General methods of cooking foods, e.g. by roasting or frying using wave energy, irradiation, electrical means or magnetic fields, e.g. oven cooking or roasting using radiant dry heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition comprising a complex of coenzyme QlO and cyclodextrins and the use thereof for the treatment of various diseases, in particular of neurodegenerative pathologic states of the central nervous system, more particu- larly of Parkinson's disease.
- Parkinson's disease is a neurodegenerative pathology wherein the component of protein degradation of Sommering' s substantia nigra causes a functional alteration thereof.
- This proteolytic stress therefore, results in a serious deficit in the production of dopamine, a cate- cholamin neurotransmitter involved in the nervous circuit of the nuclei of the base of telencephalon.
- proteins having a struc- ture that is unsuitable to their function are destroyed by the ⁇ biquitin Proteasome System (USP) complex.
- USP ⁇ biquitin Proteasome System
- the degradation process for these proteins starts with the bond of a chain of ubiquitin molecules (a protein with 76 amino acids and MW of 8,500 Da) as signal for identification and degradation by a protea- some .
- Ubiquitin monomers are activated during an ATP- dependant thioesterification by enzyme El of UPS complex.
- Activated ubiquitin is transferred to enzyme E2, a specific carrier, and then bound with covalent bonds by enzyme E3 (a ubiquitin protein ligase) to free amino groups of the lysines of the proteins to be de-
- UPS complex results in an accumulation of abnormal proteins, among which ⁇ -synuclein is crucial: in physiological conditions, this protein is involved in mechanisms of synaptic plasticity, since it manages the transport and exchange of vesicles in synaptic terminals.
- oxidative stress belongs to a sequence of events leading to neuronal death: it acts in synergy with other malfunctions, among which mitochondrial de- ficits and alterations of UPS system of degradation of cell proteins.
- Dopamine metabolism is responsible for the high levels of oxidative stress in substantia nigra: as a matter of fact, the degradation of this neurotransmitter by the enzyme monoamine oxidase produces hydrogen perox- ide (H 2 O 2 ) . This leads first to an increase in the formation of oxidized glutathione (GSSG) , which means a serious damage to the most important antioxidant system of the cell.
- GSSG oxidized glutathione
- nitric oxide causes iron to separate from ferritin, thus increasing the concentration of free iron in the cell.
- This process does not only involve dopaminergic neurons, but also occurs in glial cells, which indeed express enzymes belonging to the class of monoamine oxidases .
- glial cells which indeed express enzymes belonging to the class of monoamine oxidases .
- the task of the present invention is to prepare a composition having an inhibitory effect on the progress of neurodegenerative pathologic states of the central nervous system and in particular in Parkinson' s disease (PD) .
- an aim of the invention is to prepare a composition based on CoEnQlO, as active substance, complexed with cyclodextrins .
- Neuroprotective treatments can be useful during the onset of PD. This would mean beginning the treatment in the initial stage of the disease.
- Coenzyme QlO also known as ubiquinone or ubidecarenone
- Coenzyme QlO is a physiological molecule with antioxidant properties to be found in all cell membranes, among which inner mitochondrial membranes, where it is part of the complex I of the so- called respiratory chain, involved in the production of energy by mitochondria.
- US patent 6,861,447 B2 describes a method for producing complexes of coenzyme QlO and ⁇ - cyclodextrin by thermal or ultrasonic treatment.
- International patent application WO 2005/111224 A2 describes water-soluble complexes of coenzyme QlO and ⁇ - cyclodextrin as well as a process for producing them, in which the temperature of ⁇ -cyclodextrin dissolution in water and of the following addition of coenzyme QlO is suitably controlled.
- US patent application US 2006/0078549 describes a method for the therapeutic treatment of neurodegenerative diseases, of Huntington' s disease for instance, by administering a complex of coenzyme QlO and cyclo- dextrins .
- preparations containing CoEQlO as active substance for single-dose administrations are available at present on the mar- ket .
- Such preparations are therefore unsuitable for the treatment of neurodegenerative diseases as described above, which require quite high doses (300 mg/die to 1,200 mg/die) .
- the Applicants have faced the problem of providing preparations based on coenzyme QlO at high concentrations, having a high water solubility and a high pho- tostability, so as to enable the administration of the required dose also in a single step, preferably in liquid form or as water-soluble granules.
- the present invention therefore re- lates to a composition
- a composition comprising:
- the present invention relates to a composition as defined above for use as a medicament.
- the present invention relates to the use of a composition as defined above in the preparation of a drug for the treatment of neurodegenerative diseases of the central nervous system, in particular of Parkinson's disease (PD).
- PD Parkinson's disease
- the present invention relates to the use of a composition as defined above as food supplement .
- Cyclodextrins are cyclic oligosaccharides containing at least 6 units of D- (+) -glucopyranose bound to one another with a ⁇ , 1-4 glucoside bond.
- the three natural cyclodextrins ⁇ , ⁇ , ⁇ differ in ring size and solubility, ⁇ -cyclodextrin, ⁇ -cyclodextrin and ⁇ -cyclodextrin contain 6, 7 or 8 units of D- (+) -glucopyranose, re- spectively.
- Cyclodextrins have the appearance of fine white, basically odourless powders, with a slight sweet taste.
- ⁇ -cyclodextrin, ⁇ - cyclodextrin or ⁇ -cyclodextrin, or mixtures thereof can be used, ⁇ -cyclodextrin is particularly preferred.
- Cyclodextrins have a stiff molecular structure of frusto-conical shape, with a central cavity whose size varies depending on the number of glucopyranose units present . Due to the arrangement of hydroxyl groups, the inside of the cavity is hydrophobic, whereas the outside is hydrophilic. This configuration allows cyclodextrins to house the host molecule of coenzyme QlO inside the cavity so as to form an inclusion complex ("host- guest" complex) .
- the amount of coenzyme QlO in the composition according to the present invention is as a rule above 20% by weight, preferably of from 1% to 10% by weight, referred to the total weight of the composition.
- the composition according to the present invention comprises from 40% to 100% by weight, more preferably from 50% to 90% by weight, of at least one cyclodex- trin, the percentage being expressed referred to the weight of coenzyme QlO.
- the composition according to the present invention further comprises at least one carotene.
- Carotene is preferably selected from: ⁇ -carotene, ⁇ - carotene, lycopene, or mixtures thereof. More preferably, carotene is ⁇ -carotene.
- the composition according to the present invention comprises from 0.01% to 0.5% by weight of at least one carotene, more preferably from 0.05% to 0.3% by weight, the percentage being expressed referred to the total weight of the composition.
- carotene As is known, carotenes are commonly marketed with a content of active substance of about 1-2%, the rest being made up of suitable additives and of carotene degradation products. Obviously, the above percentages refer to carotene that is actually present in the com- position.
- composition according to the present invention solves the problems of solubility and photostability of coenzyme QlO as disclosed above, and is advantageous both for therapeutic use and for its technologi- cal properties, particularly for the flowability properties of the product.
- composition in granular form has a controlled fri- -li ⁇
- composition according to the present invention can comprise further pharmacologically acceptable excipi-
- composition according to the present invention can include at least one com- io pound selected from: lactose, maltodextrins and lipoic acid.
- the product is obtained by dividing the manufacturing process into two separate steps:
- composition according to the present invention is used as inhibitor of neurodegenerative progress, in particular in Parkinson's disease.
- the active substance acts by blocking the propagation of radical reaction, preventing the propagation thereof and therefore the lipoper- oxidation of cell membranes and thus cell death.
- Such action is enhanced by the presence of carotene which, beyond having such chemical and physical characteristics as to improve the bioavailability and pho- tostability of coenzyme QlO, performs an antioxidant action and promotes the inhibition of mechanisms producing free radicals.
- the end product can be portioned in suitable sealed containers so as to avoid any contamination from outside .
- the product thus obtained has a duration not below 24 months in suitable conditions of temperature, humidity and package integrity.
- composition according to the present invention can be used in several other diseases, such as: (a) mitochondrial diseases in general, with doses of coenzyme QlO of 1 mg/die to 10,000 mg/die;
- cardiovascular diseases in which the oxidation of low density lipoproteins (LDL) is deemed to be the essential element for the development of atherosclero- sis, with doses of coenzyme QlO of 1 mg/die to 4,000 mg/die (it is believed that coenzyme QlO, thanks to its key role in energy production, contributes to the safeguard of vascular endothelium), such as: heart diseases in general, congestive heart failure, fatigue syndrome, dyspnea, essential hypertension, angina pectoris, surgical ischemiae;
- LDL low density lipoproteins
- I 5 carotene (commercial product distributed by A. C. E. F. with a titer of 1% and fine granulometry: 95% gets through a 80 mesh sieve) in such an amount as to obtain 0.1% by weight of ⁇ -carotene referred to the total weight of the composition.
- S ⁇ concentration of coenzyme QlO (free and bound) ;
- S w intrinsic solubility;
- K f complexation constant;
- L ⁇ concentration of binder.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition contenant : (a) un complexe de coenzyme Q10 et au moins une cyclodextrine; et (b) au moins un carotène. L'invention concerne également l'utilisation de ladite composition pour le traitement de diverses maladies, en particulier de maladies neurodégénératives du système nerveux central, spécialement la maladie de Parkinson (PD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001874A ITMI20061874A1 (it) | 2006-09-29 | 2006-09-29 | Composizione per il trattamento degli stati patologici neurodegenerativi del sistema nervoso centrale ed in particolare nel morbo di parkinson |
ITMI2006A001874 | 2006-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008038119A2 true WO2008038119A2 (fr) | 2008-04-03 |
WO2008038119A3 WO2008038119A3 (fr) | 2008-11-06 |
Family
ID=39190249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/002820 WO2008038119A2 (fr) | 2006-09-29 | 2007-09-26 | Composition contenant un complexe de coenzyme q10 et de cyclodextrines et son utilisation pour le traitement de pathologies du système nerveux central |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI20061874A1 (fr) |
WO (1) | WO2008038119A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU100797B1 (en) * | 2018-05-15 | 2019-11-15 | Univ Luxembourg | 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition |
FR3117339A1 (fr) | 2020-12-16 | 2022-06-17 | Naos Institute Of Life Science | Utilisation des bactériorubérines et leurs dérivés glycosylés pour prévenir et traiter les maladies impliquant une dérégulation de l’agrégation des protéines, comme les maladies neurodégénératives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011423A2 (fr) * | 2002-07-29 | 2004-02-05 | Hawaii Biotech, Inc. | Analogues de carotenoides structuraux pour l'inhibition et la reduction de maladie |
CN1634075A (zh) * | 2004-10-28 | 2005-07-06 | 昆明翔昊科技有限公司 | 含番茄红素和辅酶q10的制剂及其制备方法 |
US7030102B1 (en) * | 2003-05-06 | 2006-04-18 | Bioactives, Llc | Highly bioavailable coenzyme Q-10 cyclodextrin complex |
EP1681053A1 (fr) * | 2003-10-31 | 2006-07-19 | Kaneka Corporation | Composition contenant une coenzyme q reduite |
-
2006
- 2006-09-29 IT IT001874A patent/ITMI20061874A1/it unknown
-
2007
- 2007-09-26 WO PCT/IB2007/002820 patent/WO2008038119A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011423A2 (fr) * | 2002-07-29 | 2004-02-05 | Hawaii Biotech, Inc. | Analogues de carotenoides structuraux pour l'inhibition et la reduction de maladie |
US7030102B1 (en) * | 2003-05-06 | 2006-04-18 | Bioactives, Llc | Highly bioavailable coenzyme Q-10 cyclodextrin complex |
EP1681053A1 (fr) * | 2003-10-31 | 2006-07-19 | Kaneka Corporation | Composition contenant une coenzyme q reduite |
CN1634075A (zh) * | 2004-10-28 | 2005-07-06 | 昆明翔昊科技有限公司 | 含番茄红素和辅酶q10的制剂及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU100797B1 (en) * | 2018-05-15 | 2019-11-15 | Univ Luxembourg | 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition |
WO2019219741A1 (fr) * | 2018-05-15 | 2019-11-21 | Université Du Luxembourg | 2-hydroxypropyl-bêta-cyclodextrine destinée à être utilisée dans une méthode de traitement d'un état parkinsonien |
FR3117339A1 (fr) | 2020-12-16 | 2022-06-17 | Naos Institute Of Life Science | Utilisation des bactériorubérines et leurs dérivés glycosylés pour prévenir et traiter les maladies impliquant une dérégulation de l’agrégation des protéines, comme les maladies neurodégénératives |
WO2022129407A1 (fr) | 2020-12-16 | 2022-06-23 | Naos Institute Of Life Science | Utilisation des bactériorubérines et leurs dérivés glycosylés pour prévenir et traiter les maladies impliquant une dérégulation de l'agrégation des protéines, comme les maladies neurodégénératives |
Also Published As
Publication number | Publication date |
---|---|
ITMI20061874A1 (it) | 2006-12-29 |
WO2008038119A3 (fr) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10342822B2 (en) | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system | |
AU2022200988B2 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
JP2008524124A (ja) | リポ酸含有シクロデキストリン複合体の使用 | |
JP5847721B2 (ja) | 高水溶性2−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物 | |
US11896598B2 (en) | Appetite suppressant compositions and methods thereof | |
US20190046598A1 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
EP2065045B1 (fr) | Anti-oxydant destiné à la prévention et au traitement de maladies liées au stress oxydatif | |
CN112870313B (zh) | 一种抑制晚期糖基化终末产物表达和抑制血管硬化的组合物及其制备方法 | |
WO2008038119A2 (fr) | Composition contenant un complexe de coenzyme q10 et de cyclodextrines et son utilisation pour le traitement de pathologies du système nerveux central | |
Lee et al. | Medicinal benefits, biological and nanoencapsulation functions of riboflavin with its toxicity profile-A narrative review | |
JP2012506429A (ja) | 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なR−(+)−α−リポ酸塩 | |
CA3074541C (fr) | Compositions de suppression de l`appetit et methodes connexes | |
WO2012014746A1 (fr) | Complexe d'acide α-lipoïque | |
WO2022108479A1 (fr) | Combinaison pour réduire le stress oxydatif dans le corps et maintenir des fonctions hépatiques | |
Madhavi et al. | A study on the bioavailability of a novel sustained-release coenzyme Q10-β-cyclodextrin complex | |
KR20200107809A (ko) | 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제 | |
JP4609890B2 (ja) | 抗うつ剤 | |
US20210023126A1 (en) | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system | |
CN115701985A (zh) | 具有硫胺素的二氢槲皮素制剂 | |
KR101026864B1 (ko) | 고 수용성 2―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 | |
WO2023233165A1 (fr) | Composition et procédé | |
WO2014185761A1 (fr) | Nouvelle composition du 3,4-diaminopyridine pour le traitement de la fatigabilite musculaire associee a des troubles neurovegetatifs | |
JP2023062717A (ja) | Nmn含有抗老化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07825195 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07825195 Country of ref document: EP Kind code of ref document: A2 |